Cloning of a novel phosphotyrosine binding domain containing molecule, Odin, involved in signaling by receptor tyrosine kinases.

Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA.
Oncogene (Impact Factor: 8.56). 12/2002; 21(52):8029-36. DOI: 10.1038/sj.onc.1205988
Source: PubMed

ABSTRACT We have used a proteomic approach using mass spectrometry to identify signaling molecules involved in receptor tyrosine kinase signaling pathways. Using affinity purification by anti-phosphotyrosine antibodies to enrich for tyrosine phosphorylated proteins, we have identified a novel signaling molecule in the epidermal growth factor receptor signaling pathway. This molecule, designated Odin, contains several ankyrin repeats, two sterile alpha motifs and a phosphotyrosine binding domain and is ubiquitously expressed. Using antibodies against endogenous Odin, we show that it undergoes tyrosine phosphorylation upon addition of growth factors such as EGF or PDGF but not by cytokines such as IL-3 or erythropoietin. Immunofluorescence experiments as well as Western blot analysis on subcellular fractions demonstrated that Odin is localized to the cytoplasm both before and after growth factor treatment. Deletion analysis showed that the phosphotyrosine binding domain of Odin is not required for its tyrosine phosphorylation. Overexpression of Odin, but not an unrelated adapter protein, Grb2, inhibited EGF-induced activation of c-Fos promoter. Microinjection of wild-type or a mutant version lacking the PTB domain into NIH3T3 fibroblasts inhibited PDGF-induced mitogenesis. Taken together, our results indicate that Odin may play a negative role in growth factor receptor signaling pathways.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Advances in microcapillary liquid chromatography tandem mass spectrometry (LC–MS/MS), in combination with the completion of genome sequencing projects, have opened the door to systematic large-scale mammalian protein expression profiling. The aim of this emerging field is to gain insight into the systems biology of complex multicellular organisms. A recently developed multistep analytical strategy, called PRISM (proteome investigation strategy for mammals), is a promising technology platform for investigating the complex proteome of mammalian tissues.
    Drug Discovery Today TARGETS 04/2004; 3(2):37-42. DOI:10.1016/S1741-8372(04)02422-3
  • [Show abstract] [Hide abstract]
    ABSTRACT: Post-translational modification of proteins with the small polypeptide ubiquitin plays a pivotal role in many cellular processes altering protein lifespan, location, function, and regulating protein-protein interactions. Ubiquitination exerts its diverse functions through complex mechanisms by formation of different polymeric chains and subsequent recognition of the ubiquitin signal by specific protein interaction domains. Despite some recent advances in the analytical tools for analysis of ubiquitination by mass spectrometry, there is still a need for additional strategies suitable for investigation of cellular ubiquitination at the proteome level. Here, we present a Stable Tagged Ubiquitin Exchange (StUbEx) cellular system, in which the endogenous ubiquitin is replaced with an epitope-tagged version, thereby allowing specific and efficient affinity purification of ubiquitinated proteins for global analyses of protein ubiquitination. Importantly, the overall level of ubiquitin in the cell remains virtually unchanged, thus avoiding ubiquitination artifacts associated with over-expression. The efficiency and reproducibility of the method were assessed through unbiased analysis of epidermal growth factor (EGF) signaling by quantitative mass spectrometry, covering over 3400 potential ubiquitinated proteins. The StUbEx system is applicable to virtually any cell line and can readily be adapted to any of the ubiquitin-like post-translational modifications.
    Journal of Proteome Research 08/2014; DOI:10.1021/pr500549h · 5.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ligand-stimulated epidermal growth factor receptor (EGFR) has been extensively studied in the analysis of molecular mechanisms regulating endocytic traffic and the role of that traffic in signal transduction. Although such studies have largely focused on mitogenic signaling and dysregulated traffic in tumorigenesis, there is growing interest in the potential role of EGFR traffic in cell survival and the consequent response to cancer therapy. Here we review recent advances in our understanding of molecular mechanisms regulating ligand-stimulated EGFR activation, internalization, and post-endocytic sorting. The role of EGFR overexpression/mutation and new modulators of EGFR traffic in cancer and the response to cancer therapeutics are also discussed. Finally, we speculate on the relationship between EGFR traffic and cell survival.
    Trends in cell biology 11/2013; DOI:10.1016/j.tcb.2013.11.002 · 12.12 Impact Factor

Full-text (2 Sources)

Available from
Mar 4, 2015